OPK Long Call Strategy
OPK (OPKO Health, Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NASDAQ.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico.
OPK (OPKO Health, Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $838.2M, a beta of 1.41 versus the broader market, a 52-week range of 0.98-1.6, average daily share volume of 2.8M, a public-listing history dating back to 1995, approximately 3K full-time employees. These structural characteristics shape how OPK stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.41 indicates OPK has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on OPK?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current OPK snapshot
As of May 15, 2026, spot at $1.10, ATM IV 48.40%, IV rank 7.63%, expected move 13.88%. The long call on OPK below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on OPK specifically: OPK IV at 48.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a OPK long call, with a market-implied 1-standard-deviation move of approximately 13.88% (roughly $0.15 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated OPK expiries trade a higher absolute premium for lower per-day decay. Position sizing on OPK should anchor to the underlying notional of $1.10 per share and to the trader's directional view on OPK stock.
OPK long call setup
The OPK long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With OPK near $1.10, the first option leg uses a $1.10 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed OPK chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 OPK shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.10 | N/A |
OPK long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
OPK long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on OPK. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on OPK
Long calls on OPK express a bullish thesis with defined risk; traders use them ahead of OPK catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
OPK thesis for this long call
The market-implied 1-standard-deviation range for OPK extends from approximately $0.95 on the downside to $1.25 on the upside. A OPK long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current OPK IV rank near 7.63% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on OPK at 48.40%. As a Healthcare name, OPK options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to OPK-specific events.
OPK long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. OPK positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move OPK alongside the broader basket even when OPK-specific fundamentals are unchanged. Long-premium structures like a long call on OPK are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current OPK chain quotes before placing a trade.
Frequently asked questions
- What is a long call on OPK?
- A long call on OPK is the long call strategy applied to OPK (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With OPK stock trading near $1.10, the strikes shown on this page are snapped to the nearest listed OPK chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are OPK long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the OPK long call priced from the end-of-day chain at a 30-day expiry (ATM IV 48.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a OPK long call?
- The breakeven for the OPK long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current OPK market-implied 1-standard-deviation expected move is approximately 13.88%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on OPK?
- Long calls on OPK express a bullish thesis with defined risk; traders use them ahead of OPK catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current OPK implied volatility affect this long call?
- OPK ATM IV is at 48.40% with IV rank near 7.63%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.